TTNP Valuation

Titan Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.210

-0.1(-2.320%)1D

Overview
Forecast
Valuation
Earnings

TTNP Relative Valuation

TTNP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TTNP is overvalued; if below, it's undervalued.

Historical Valuation

Titan Pharmaceuticals Inc (TTNP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.33. The fair price of Titan Pharmaceuticals Inc (TTNP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.21

Fair

-0.49

Trailing

Forward

0.00

EV/EBITDA

Titan Pharmaceuticals Inc. (TTNP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.03. The thresholds are as follows: Strongly Undervalued below -0.19, Undervalued between -0.19 and -0.08, Fairly Valued between 0.14 and -0.08, Overvalued between 0.14 and 0.25, and Strongly Overvalued above 0.25. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.43

EV/EBIT

Titan Pharmaceuticals Inc. (TTNP) has a current EV/EBIT of -0.43. The 5-year average EV/EBIT is -0.60. The thresholds are as follows: Strongly Undervalued below -1.83, Undervalued between -1.83 and -1.21, Fairly Valued between 0.01 and -1.21, Overvalued between 0.01 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBIT of -0.43 falls within the Historic Trend Line -Fairly Valued range.

0.81

Titan Pharmaceuticals Inc. (TTNP) has a current PS of 0.81. The 5-year average PS is 54.78. The thresholds are as follows: Strongly Undervalued below -117.54, Undervalued between -117.54 and -31.38, Fairly Valued between 140.94 and -31.38, Overvalued between 140.94 and 227.10, and Strongly Overvalued above 227.10. The current Forward PS of 0.81 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Titan Pharmaceuticals Inc. (TTNP) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.05. The thresholds are as follows: Strongly Undervalued below -0.27, Undervalued between -0.27 and -0.11, Fairly Valued between 0.20 and -0.11, Overvalued between 0.20 and 0.36, and Strongly Overvalued above 0.36. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.65

P/FCF

Titan Pharmaceuticals Inc. (TTNP) has a current P/FCF of -0.65. The 5-year average P/FCF is -0.63. The thresholds are as follows: Strongly Undervalued below -1.80, Undervalued between -1.80 and -1.22, Fairly Valued between -0.04 and -1.22, Overvalued between -0.04 and 0.55, and Strongly Overvalued above 0.55. The current Forward P/FCF of -0.65 falls within the Historic Trend Line -Fairly Valued range.

Titan Pharmaceuticals Inc (TTNP) has a current Price-to-Book (P/B) ratio of 2.01. Compared to its 3-year average P/B ratio of -1.85 , the current P/B ratio is approximately -208.47% higher. Relative to its 5-year average P/B ratio of -0.94, the current P/B ratio is about -313.14% higher. Titan Pharmaceuticals Inc (TTNP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -103.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -91.33% , the current FCF yield is about -100.00% lower.

2.01

P/B

Median3y

-1.85

Median5y

-0.94

-47.90

FCF Yield

Median3y

-103.88

Median5y

-91.33

Competitors Valuation Multiple

The average P/S ratio for TTNP's competitors is 0.00, providing a benchmark for relative valuation. Titan Pharmaceuticals Inc Corp (TTNP) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TTNP.O

Titan Pharmaceuticals Inc

XORTX Therapeutics Inc

Loss

4.53M

RDHL.O

Redhill Biopharma Ltd

Pasithea Therapeutics Corp

Loss

5.43M

SILO.O

Silo Pharma Inc (Pre-Reincorporation)

Loss

0.00%

7.41M

Performance Decomposition

Market capitalization of TTNP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of TTNP in the past 1 year is driven by Unknown.